Bulletin
Investor Alert

Market Pulse Archives

June 1, 2020, 7:58 a.m. EDT

Regeneron to expand development deal with Intellia Therapeutics

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Regeneron Pharmaceuticals Inc. (REGN)
  • X
    Intellia Therapeutics Inc. (NTLA)
  • X
    Sanofi ADR (SNY)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Regeneron Pharmaceuticals Inc. /zigman2/quotes/203149337/composite REGN +2.18% were down 0.5% in premarket trading on Monday after the company said it had expanded a collaboration with Intellia Therapeutics Inc. /zigman2/quotes/207821052/composite NTLA +1.36% to include CRISPR/Cas9-based therapeutic targets and a new focus on developing treatments for hemophilia A and B. Intellia's stock was up 23.6% before the market opened. Regeneron will pay $70 million upfront and make a $30 million equity investment in Intellia at $32.42 per share. Regeneron recently wrapped up a longtime development arrangement with Sanofi /zigman2/quotes/201967021/composite SNY +0.68% . Year-to-date, Regeneron's stock is up 63.2%, shares of Intellia have gained 19.3%, and the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.45% is down 5.7%.

/zigman2/quotes/203149337/composite
US : U.S.: Nasdaq
$ 622.45
+13.28 +2.18%
Volume: 0.00
July 2, 2020 4:00p
P/E Ratio
31.28
Dividend Yield
N/A
Market Cap
$70.04 billion
Rev. per Employee
$906,865
loading...
/zigman2/quotes/207821052/composite
US : U.S.: Nasdaq
$ 22.30
+0.30 +1.36%
Volume: 0.00
July 2, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.27 billion
Rev. per Employee
$144,237
loading...
/zigman2/quotes/201967021/composite
US : U.S.: Nasdaq
$ 51.62
+0.35 +0.68%
Volume: 0.00
July 2, 2020 4:00p
P/E Ratio
39.98
Dividend Yield
2.27%
Market Cap
$129.70 billion
Rev. per Employee
$390,092
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,130.01
+14.15 +0.45%
Volume: 0.00
July 2, 2020 5:19p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.